ComMIT Biologics

Activating the complement system offers an efficient #immune mechanism for clearing #pathogens, maintaining immune homeostasis, and stimulating adaptive immune responses.    However, complement is inherently difficult to activate with monoclonal antibodies and is currently underexploited in the treatment of both #cancer and #autoimmune disease.    Complement activation leverages both the body’s innate and adaptive defences and can be very fast-acting and potent. Unleashing this power with Commit Biologics' technology can direct the complement system in a highly targeted way to cells of interest, leading to selective cell killing.   Visit our website using the link in the comments below to find out more.    #ComplementSystem #ImmuneSystem #antibodies

Great to see Commit Biologics featured in BioCentury Inc.’s Emerging Company Profile series🚀!   It comes after our CEO, Krishna Polu spoke to BioCentury Inc.'s Danielle Golovin, Ph.D. about Commit Biologics' novel approach to activating the complement pathway. In the piece, Krishna discusses how our bispecific complement engager (BiCE) technology engages C1q to trigger highly selective complement-induced killing of #cancer or #autoimmune cells. You can read more using the link below 👇 #ComplementSystem #ImmuneSystem #BioCentury

Commit Biologics welcomes Mikkel Wandahl Pedersen, as its new Chief Scientific Officer🚀   With over two decades of experience in #antibody-based drug discovery and development, Mikkel further strengthens our leadership team as we continue to advance our Bispecific Complement Engaging (#BiCE™) technology, designed to revolutionise treatments for #cancer and #autoimmune disease. 💊   Mikkel joins us from Nykode Therapeutics where, as CSO, he successfully created and executed a new research strategy, scaled the research organisation to support an expanding pipeline, and spearheaded key collaborations with external pharmaceutical partners.   He brings to Commit a wealth of knowledge in #immunooncology and #autoimmune research   To learn more about Mikkel's background see the press release, linked in the comments below 👇.   #CSO #Leadership #ComplementSystem

To biotech-spinouts fra Aarhus Universitet er på europæisk top 10 over de vigtigste biotech-virksomheder lige nu 💡🚀 Både Draupnir Bio og ComMIT Biologics, der er udsprunget fra hhv. Health - Aarhus University og Faculty of Natural Sciences - Aarhus University er de to eneste danske biotech-spinouts på europæisk top 10-liste over biotech-virksomheder, man skal holde godt øje med fremover. Placeringen på listen signalerer tydeligt, at Aarhus og Aarhus Universitet har etableret sig som en stærk biotech-hub i Europa. Listen er udgivet af et af Europas største biotech-medier, Labiotech.eu Draupnir Bio er stiftet af Simon Glerup og Camilla Gustafsen i 2017 og udvikler nye behandlingsmidler til at transformere behandlingen af hjertesygdomme. ComMit Biologics er stiftet i 2023 af hhv. Nick Stub Laursen, Dennis Pedersen, Mikael B. L. Winkler og Heidi Gytz Olesen. ComMit Biologics udvikler immunterapi til behandling af bl.a. cancer. Stort tillykke til de to biotech-virksomheder 👏✨ Læs nyheden her https://lnkd.in/dx5kkqqM #værditilsamfundet #biotech #wheresciencemeetslife Jeppe Dørup Olesen Morten Holmager Health Innovation Aarhus

📣 Commit Biologics Bio has been recognised as one of 'Europe’s rising biotech stars: 10 startups to watch in 2024' by @Labiotech.eu!   Since emerging from stealth in May this year, backed by €16m seed financing from Bioqube Ventures and Novo Holdings, we have been working to advance our ‘BiCE’ (Bispecific Complement Engaging) platform to transform the treatment of #cancer and #autoimmune disease.   We are just getting started!   Read the full article here: https://bitly.cx/zBhV

This Thursday, our CEO Krishna Polu will be representing Commit Biologics at the Novo Holdings annual Seed Summit.    We are proud to be among the select few companies invited to present and look forward to showcasing our groundbreaking #BiCEtechnology platform, which has the potential to transform the treatment of #cancer and #autoimmune diseases.   #NovoHoldings #Antibodies #Complement

We’re thrilled that Commit Biologics has been nominated as 'Startup of the year' for the 2024 INCUBA A/S awards! 🏅   It’s an honour to be recognised among the startups that are driving innovation, making a real impact and helping to grow our local start up community.   Best of luck to all the nominees 🎉   #Startupoftheyear

Very pleased to be a finalist of the ‘Seed Raise of the Year’ category of the European Lifestars Awards - Celebrating Life Science Leaders 🏆 The Commit Biologics team is looking forward to the Awards Ceremony in London in November!   Good luck to all finalists ✨   #LifestarsAwards LSX - partnering for Life Science eXecutives  

🎉 Celebrating 3 years of Commit Biologics! 🎉   On September 1st, 2021, our co-founders Nick Stub Laursen, Dennis Pedersen, Mikael B. L. Winkler, and Heidi Gytz Olesen joined forces at Aarhus University in Denmark to bring Commit Biologics to life.    Since then, we’ve built a world-class team with exceptional academic and international industry expertise, and this year, we proudly emerged from stealth with a successful €16M seed financing round.   We’re just getting started, and we’re incredibly proud of how far we’ve come in just three years. Here’s to many more milestones and birthdays for Commit Biologics!    #ComplementSystem #Antibodies #Anniversary

Next week, our COO and Co-Founder, Dennis Pedersen and CDO, Pascal Merchiers will be attending the 19th European Meeting on Complement in Human Diseases in Lübeck, Germany.     If you will also be attending and would like to learn about Commit Biologics' novel method to activate the complement system, get in touch!   #EMCHD2024 #ComplementSystem #BiCE #Antibodies